Gene · 7045
Papers3,774
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,774
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Metabolomic, Lipidomic, Transcriptomic, and Metagenomic Analyses in Mice Exposed to PFOS and Fed Soluble and Insoluble Dietary Fibers. | Environ Health Perspect | 2022 | 36331819 | PubTator, text mining | PubMed |
| Uncover diagnostic immunity/hypoxia/ferroptosis/epithelial mesenchymal transformation-related CCR5, CD86, CD8A, ITGAM, and PTPRC in kidney transplantation patients with allograft rejection. | Ren Fail | 2022 | 36330810 | PubTator, text mining | PubMed |
| Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review. | Expert Rev Clin Pharmacol | 2022 | 36308770 | PubTator, text mining | PubMed |
| Autosomal recessive LRP1-related syndrome featuring cardiopulmonary dysfunction, bone dysmorphology, and corneal clouding. | Cold Spring Harb Mol Case Stud | 2022 | 36307211 | PubTator, text mining | PubMed |
| Identification of Immune and Hypoxia Risk Classifier to Estimate Immune Microenvironment and Prognosis in Cervical Cancer. | J Oncol | 2022 | 36304989 | PubTator, text mining | PubMed |
| Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer. | Front Oncol | 2022 | 36300085 | PubTator, text mining | PubMed |
| Vitamin K Contribution to DNA Damage-Advantage or Disadvantage? A Human Health Response. | Nutrients | 2022 | 36296903 | PubTator, text mining | PubMed |
| Expression Pattern of Tenascin-C, Matrilin-2, and Aggrecan in Diseases Affecting the Corneal Endothelium. | J Clin Med | 2022 | 36294311 | PubTator, text mining | PubMed |
| Identification of genetic variants in five chinese families with keratoconus: Pathogenicity analysis and characteristics of parental corneal topography. | Front Genet | 2022 | 36276932 | PubTator, text mining | PubMed |
| Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma. | Front Oncol | 2022 | 36276140 | PubTator, text mining | PubMed |
| Origin, activation, and targeted therapy of glioma-associated macrophages. | Front Immunol | 2022 | 36275720 | PubTator, text mining | PubMed |
| Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy. | ACS Nano | 2022 | 36256454 | PubTator, text mining | PubMed |
| Autophagy in the normal and diseased cornea. | Exp Eye Res | 2022 | 36252655 | PubTator, text mining | PubMed |
| Neurosurgery outcomes and complications in a monocentric 7-year patient registry. | Brain Spine | 2022 | 36248111 | PubTator, text mining | PubMed |
| Exploration of N6-Methyladenosine Profiles of mRNAs and the Function of METTL3 in Atherosclerosis. | Cells | 2022 | 36230944 | PubTator, text mining | PubMed |
| Single-Cell Gene Expression Analysis Revealed Immune Cell Signatures of Delta COVID-19. | Cells | 2022 | 36230912 | PubTator, text mining | PubMed |
| Evaluation of the Cellular Dissociation Grading, Based on Tumor Budding and Cell Nest Size, in Squamous Cell Carcinoma of the Penis. | Cancers (Basel) | 2022 | 36230870 | PubTator, text mining | PubMed |
| Transcriptome Analysis Identifies Accumulation of Natural Killer Cells with Enhanced Lymphotoxin-β Expression during Glioblastoma Progression. | Cancers (Basel) | 2022 | 36230839 | PubTator, text mining | PubMed |
| Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma. | Cancers (Basel) | 2022 | 36230815 | PubTator, text mining | PubMed |
| Periostin: biology and function in cancer. | Cancer Cell Int | 2022 | 36224629 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7045/papers?page=36